SteelPeak Wealth LLC Invests $644,000 in Illumina, Inc. $ILMN

SteelPeak Wealth LLC acquired a new position in Illumina, Inc. (NASDAQ:ILMN) during the 1st quarter, according to its most recent filing with the SEC. The fund acquired 5,227 shares of the life sciences company’s stock, valued at approximately $644,000.

A number of other large investors have also recently added to or reduced their stakes in ILMN. Invesco Ltd. raised its position in Illumina by 97.0% during the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after acquiring an additional 1,352,731 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after purchasing an additional 1,028,099 shares during the last quarter. Morgan Stanley increased its stake in shares of Illumina by 66.0% during the 4th quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock worth $331,710,000 after purchasing an additional 1,005,474 shares in the last quarter. Nordea Investment Management AB increased its stake in shares of Illumina by 2,792.2% during the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after purchasing an additional 911,843 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. purchased a new position in shares of Illumina during the 1st quarter worth approximately $106,462,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Illumina

In other news, Director Keith A. Meister sold 235,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the sale, the director owned 2,830,452 shares in the company, valued at $463,146,860.76. This trade represents a 7.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This represents a 3.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,003,769 shares of company stock worth $155,710,908. Company insiders own 2.90% of the company’s stock.

Illumina Stock Performance

NASDAQ:ILMN opened at $186.65 on Friday. The firm has a 50 day simple moving average of $166.44 and a 200-day simple moving average of $143.34. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The firm has a market cap of $28.24 billion, a PE ratio of 33.94, a P/E/G ratio of 3.49 and a beta of 1.47. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $196.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. Illumina’s revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities analysts expect that Illumina, Inc. will post 5.22 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on ILMN. Leerink Partners upped their target price on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research note on Friday. Citigroup raised their price target on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research report on Monday, May 4th. Evercore reissued an “outperform” rating on shares of Illumina in a report on Monday, July 6th. Guggenheim upped their price objective on Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Finally, Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Nine investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and a consensus price target of $156.88.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.